SIGA Technologies, Inc. - Form 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2010. SIGA Technologies, Inc. is a bio-defense company focused on the discovery, development, and commercialization of products to defend against biological warfare agents, such as smallpox and arenaviruses. The Company has no commercial products and relies on government grants, contracts, and financing to fund operations.
Key Financial Metrics
| Metric | Q1 2010 | Q1 2009 |
|---|---|---|
| Revenues | $5,075,211 | $1,925,777 |
| Operating Expenses | $8,116,153 | $4,865,543 |
| Operating Loss | $(3,040,942) | $(2,939,766) |
| Net Loss | $(4,409,458) | $(6,884,501) |
| Net Loss Per Share (Basic/Diluted) | $(0.10) | $(0.19) |
| Cash and Cash Equivalents | $8,508,027 | $1,563,660 |
| Short-Term Investments | $8,749,925 | N/A |
| Total Liabilities | $16,276,591 | $15,426,796 |
| Stockholders' Equity | $7,438,859 | $10,488,491 |
Cash Flow: Net cash used in operating activities was $3.2 million. Net cash used in investing activities was $3.9 million, primarily due to the purchase of short-term investments. Net cash provided by financing activities was $1.1 million from the exercise of warrants and options.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 164% to $5.1 million, driven by a $2.4 million increase in revenue from large-scale manufacturing of the lead drug candidate ST-246 and new federal awards.
- Expense Increase: Operating expenses rose 67% to $8.1 million. Research and Development (R&D) expenses increased 116% to $5.8 million, primarily due to costs for large-scale manufacturing and clinical testing of ST-246.
- Net Loss Improvement: Net loss decreased to $4.4 million from $6.9 million in the prior year. This improvement was largely due to a reduction in the loss associated with the fair value adjustment of common stock warrants ($1.4 million loss in 2010 vs. $3.9 million in 2009).
- Liquidity: Cash and cash equivalents decreased from $14.5 million at year-end 2009 to $8.5 million, while short-term investments increased to $8.7 million.
Outlook, Risks, and Contingencies
- New Contract: In February 2010, SIGA was awarded a $2.8 million contract (with options for up to $9.9 million) from the Department of Defense to support the pre-clinical development of a broad-spectrum antiviral drug candidate.
- Liquidity Outlook: Management believes existing funds and anticipated government grants will support operations for at least the next 12 months. However, the Company expects to incur additional losses and will require future financing to complete product development.
- Legal Proceedings: PharmAthene, Inc. is suing SIGA regarding the ST-246 drug candidate, seeking a license agreement and damages up to $1 billion. SIGA believes it has meritorious defenses, but no trial date is set, and the potential loss is currently indeterminable.
- Related Party Commitment: A letter agreement with MacAndrews & Forbes, LLC allows for up to $8 million in investment; $5.5 million remains available as of March 31, 2010.
Investor Verification Checklist
- Verify the status and potential financial impact of the PharmAthene litigation, specifically the $1 billion damages claim.
- Monitor the execution of the new $2.8 million DoD contract and the likelihood of exercising the $9.9 million options.
- Assess the timeline for ST-246 clinical trials and the associated cash burn rate, given the significant increase in R&D expenses.
- Review the fair value adjustments on stock warrants, which significantly impact reported net loss but are non-cash items.
- Confirm the sufficiency of the $17.2 million total liquid assets (cash + short-term investments) to fund operations through the next 12 months without additional equity dilution.